The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/05/Yaakov-Stern-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/05/Jackie-French-Interview-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/05/Movement-Disorder-Initial-Manifestation-of-Hereditary-Hemochromatosis-A-Case-Report-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/05/NEU_Article_Tics-Temporally-Associated-with-940x564.png)